In the case of prostate cancer, the TMPRSS2–ERG fusion leads to upregulation of the ETS transcription factor ERG [94], which drives invasion and migration of prostate cancer cells and restricts their differentiation capacity [95]. This evidence concerns the gene ERG and prostate carcinoma.